The endothelium is more than just a passive vessel lining. New advances have revealed and expanded the multifactorial role of the endothelium in the homeostatic regulation of the microvasculature, including control of primary hemostasis, blood coagulation and fibrinolysis, platelet and leukocyte interactions with the vessel wall, lipoprotein metabolism, presentation of histocompatibility antigens, regulation of vascular tone and growth, and regulation of blood pressure. It possesses numerous receptors and releases compounds that affect the regulation of vascular tone and contribute to vascular permeability. Many crucial vasoactive endogenous compounds are formed in the endothelial cells to control the functions of vascular smooth muscle cells and circulating blood cells. Gap junctions facilitate the exchange of metabolites, ions, and other messenger molecules among endothelial cells and smooth muscle cells, and regulate cell growth. Among the numerous regulatory systems affecting microvascular function are the cholinergic and adrenergic (α1, α2, and β) systems. Flow-metabolism coupling is affected by a variety of signaling systems, including adenosine, oxygen, carbon dioxide, lactate, nitric oxide, and others. Agents such as the angiotensin system and endothelin, as well as others, play a role in autoregulation (maintenance of constant flow in the face of changing pressure). All of these are discussed in detail.
Get full access to this article
View all access options for this article.
References
1.
1. Cocks TM, Angus JA: Endothelium-dependent relaxation of coronary arteries by noradrenaline and serotonin. Nature305:627-630, 1983.
2.
2. Angus JA, Cocks TM, Satoh K: The alpha adrenoceptors on endothelial cells. Fed Proc45:2355-2359, 1986.
3.
3. Vanhoutte PM, Miller VM: Alpha 2-adrenoceptors and endothelium-derived relaxing factor. Am J Med87:1S-5S, 1989.
4.
4. Richard V, Tanner FC, Tschudi M, et al: Different activation of L-arginine pathway by bradykinin, serotonin, and clonidine in coronary arteries. Am J Physiol259:H1433-H1439, 1990.
5.
5. Bockman CS, Jeffries WB, Abel PW: Binding and functional characterization of alpha-2 adrenergic receptor subtypes on pig vascular endothelium. J Pharmacol Exp Ther267:1126-1133, 1993.
6.
6. Bockman CS, Gonzalez-Cabrera I, Abel PW: Alpha-2 adrenoceptor subtype causing nitric oxide-mediated vascular relaxation in rats. J Pharmacol Exp Ther278:1235-1243, 1996.
7.
7. Dawes M, Chowienczyk PJ, Ritter JM: Effects of inhibition of the L-arginine/nitric oxide pathway on vasodilation caused by beta-adrenergic agonists in human forearm. Circulation95:2293-2297, 1997.
8.
8. Ferro A, Queen LR, Priest RM, et al: Activation of nitric oxide synthase by beta 2-adrenoceptors in human umbilical vein endothelium in vitro. Br J Pharmacol126:1872-1880, 1999.
9.
9. Gray DW, Marshall I: Novel signal transduction pathway mediating endothelium-dependent beta-adrenoceptor vasorelaxation in rat thoracic aorta. Br J Pharmacol107:684-690, 1992.
10.
10. Schwinn DA, Lomasney JW, Lorenz W, et al: Molecular cloning and expression of the cDNA for a novel alpha 1-adrenergic receptor subtype. J Biol Chem265:8183-8189, 1990.
11.
11. Cotecchia S, Schwinn DA, Randall RR, et al: Molecular cloning and expression of the cDNA for the hamster alpha 1-adrenergic receptor. Proc Natl Acad Sci USA85:7159-7163, 1988.
12.
12. Perez DM, Piascik MT, Graham RM: Solution-phase library screening for the identification of rare clones: Isolation of an alpha lD-adrenergic receptor cDNA. Mol Pharmacol40:876-883, 1991.
13.
13. Bylund DB, Eikenberg DC, Hieble JP, et al: International Union of Pharmacology nomenclature of adrenoceptors. Pharmacol Rev46:121-136, 1994.
14.
14. Ford AP, Williams TJ, Blue DR, et al: Alpha 1-adrenoceptor classification: Sharpening Occam's razor. Trends Pharmacol Sci15:167-170, 1994.
15.
15. Hein L, Kobilka BK: Adrenergic receptor signal transduction and regulation. Neuropharmacology34:357-366, 1995.
17. Garcia-Sainz JA, Vazquez-Prado J, del Carmen Medina L: Alpha 1-adrenoceptors: Function and phosphorylation. Eur J Pharmacol389:1-12, 2000.
18.
18. Yang M, Ruan J, Voller M, et al: Differential regulation of human alphal-adrenoceptor subtypes. Naunyn Schmiedebergs Arch Pharmacol359:439-446, 1999.
19.
19. Flavahan NA, Cooke JP, Shepherd JT, et al: Human postjunctional alpha-i and alpha-2 adrenoceptors: Differential distribution in arteries of the limbs. J Pharmacol Exp Ther241:361-365, 1987.
20.
20. Bylund DB, Blaxall HS, Iversen LJ, et al: Pharmacological characteristics of alpha 2-adrenergic receptors: Comparison of pharmacologically defined subtypes with subtypes identified by molecular cloning. Mol Pharmacol42:1-5, 1992.
21.
21. Nahorski SR, Barnett DB, Cheung YD: Alpha-adrenoceptor-effector coupling: Affinity states or heterogeneity of the alpha 2-adrenoceptor?Clin Sci (Lond)68:39s-42s, 1985.
22.
22. Bylund DB, Ray-Prenger C, Murphy TJ: Alpha-2A and alpha-2B adrenergic receptor subtypes: Antagonist binding in tissues and cell lines containing only one subtype. J Pharmacol Exp Ther245:600-607, 1988.
24. Alabaster VA, Keir RF, Peters CJ: Comparison of potency of alpha 2-adrenoceptor antagonists in vitro: Evidence for heterogeneity of alpha 2-adrenoceptors. Br J Pharmacol88:607-614, 1986.
25.
25. Cotecchia S, Kobilka BK, Daniel KW, et al: Multiple second messenger pathways of alpha-adrenergic receptor subtypes expressed in eukaryotic cells. J Biol Chem265:63-69, 1990.
26.
26. Wise A, Watson-Koken MA, Rees S, et al: Interactions of the alpha2A-adrenoceptor with multiple G1-family Gpro-teins: Studies with pertussis toxin-resistant G-protein mutants. Biochem J321:721-728, 1997.
27.
27. Surprenant A, Horstman DA, Akbarali H, et al: A point mutation of the alpha 2-adrenoceptor that blocks coupling to potassium but not calcium currents. Science257:977-980, 1992.
28.
28. Eason MG, Liggett SB: Subtype-selective desensitization of alpha 2-adrenergic receptors. Different mechanisms control short and long term agonist-promoted desensitization of alpha 2C10, alpha 2C4, and alpha 2C2. J Biol Chem267:25473-25479, 1992.
29.
29. Heck DA, Bylund DB: Differential down-regulation of alpha-2 adrenergic receptor subtypes. Life Sci62:1467-1472, 1998.
31. Langer SZ: 25 years since the discovery of presynaptic receptors: Present knowledge and future perspectives. Trends Pharmacol Sci18:95-99, 1997.
32.
32. Muller-Schweinitzer E: Alpha-adrenoceptors, 5-hydroxytryptamine receptors and the action of dihydroergotamine in human venous preparations obtained during saphenectomy procedures for varicose veins. Naunyn Schmiedebergs Arch Pharmacol327:299-303, 1984.
33.
33. Guimaraes S, Nunes JP: The effectiveness of alpha 2-adrenoceptor activation increases from the distal to the proximal part of the veins of canine limbs. Br J Pharmacol101:387-393, 1990.
34.
34. Molenaar P, Malta E, Jones CR, et al: Autoradiographic localization and function of beta-adrenoceptors on the human internal mammary artery and saphenous vein. Br J Pharmacol95:225-233, 1988.
35.
35. Rohrer DK, Chruscinski A, Schauble EH, et al: Cardiovascular and metabolic alterations in mice lacking both betal-and beta2-adrenergic receptors. J Biol Chem274:16701-16708, 1999.
36.
36. Dixon RA, Kobilka BK, Strader DJ, et al: Cloning of the gene and cDNA for mammalian beta-adrenergic receptor and homology with rhodopsin. Nature321:75-79, 1986.
37.
37. Frielle T, Collins S, Daniel KW, et al: Cloning of the cDNA for the human beta 1-adrenergic receptor. Proc Natl Acad Sci USA84:7920-7924, 1987.
38.
38. Emorine LJ, Marullo S. Briend-Sutren MM, et al: Molecular characterization of the human beta 3-adrenergic receptor. Science245:1118-1121, 1989.
39.
39. Brown AM: Regulation of heartbeat by G protein-coupled ion channels. Am J Physiol259:H1621-H1628, 1990.
40.
40. Asano T, Katada T, Gilman AG, et al: Activation of the inhibitory GTP-binding protein of adenylate cyclase, Gi, by beta-adrenergic receptors in reconstituted phospholipid vesicles. J Biol Chem259:9351-9354, 1984.
41.
41. Chaudhry A, MacKenzie RG, Georgic LM, et al: Differential interaction of beta 1-and beta 3-adrenergic receptors with Gi in rat adipocytes. Cell Signal6:457-465, 1994.
42.
42. Luttrell LM, Ferguson SS, Daaka Y, et al: Beta-arrestin-dependent formation of beta2 adrenergic receptor-Src protein kinase complexes. Science283:655-661, 1999.
43.
43. Bunemann M, Lee KB, Pals-Rylaarsdam R, et al: Desensitization of G-protein-coupled receptors in the cardiovascular system. Annu Rev Physiol61:169-192, 1999.
44.
44. O'Donnell SR, Wanstall JC: Responses to the beta 2-selective agonist procaterol of vascular and atrial preparations with different functional beta-adrenoceptor populations. Br J Pharmacol84:227-235, 1985.
45.
45. Begonha R, Moura D, Guimaraes S: Vascular beta-adrenoceptor-mediated relaxation and the tone of the tissue in canine arteries. J Pharm Pharmacol47:510-5131995.
46.
46. Edvinsson L, Owman C: Pharmacological characterization of adrenergic alpha and beta receptors mediating the vasomotor responses of cerebral arteries in vitro. Circ Res35:835-849, 1974.
47.
47. Guimaraes S: Further study of the adrenoceptors of the saphenous vein of the dog: Influence of factors which interfere with the concentrations of agonists at the receptor level. Eur J Pharmacol34:9-19, 1975.
48.
48. Sparks HV Jr, Bardenheuer H: Regulation of adenosine formation by the heart. Circ Res58:193-201, 1986.
49.
49. Schwartz LM, Bukowski TR, Ploger JD, et al: Endothelial adenosine transporter characterization in perfused guinea pig hearts. Am J Physiol Heart Circ Physiol279:H1502-H1511, 2000.
50.
50. Tucker AL, Linden J: Cloned receptors and cardiovascular responses to adenosine. Cardiovasc Res27:62-67, 1993.
51.
51. Linden J: Cloned adenosine A3 receptors: Pharmacological properties, species differences and receptor functions. Trends Pharmacol Sci15:298-306, 1994.
52.
52. Fredholm BB, Abbracchio MP, Burnstock G, et al: Nomenclature and classification of purinoceptors. Pharmacol Rev46:143-156, 1994.
53.
53. Olah ME, Stiles GL: Adenosine receptor subtypes: Characterization and therapeutic regulation. Annu Rev Pharmacol Toxicol35:581-606, 1995.
54.
54. Fredholm BB, Arslan G, Halldner L, et al: Structure and function of adenosine receptors and their genes. Naunyn Schmiedebergs Arch Pharmacol362:364-374, 2000.
55.
55. Freissmuth M, Schutz W, Linder ME: Interactions of the bovine brain Al-adenosine receptor with recombinant G protein alpha-subunits. Selectivity for rGi alpha-3. J Biol Chem266:17778-17783, 1991.
56.
56. Munshi R, Pang IH, Sternweis PC, et al: Al adenosine receptors of bovine brain couple to guanine nucleotidebinding proteins Gil, Gi2, and Go. J Biol Chem266:22285-22289, 1991.
57.
57. Abebe W, Mustafa SJ: Al adenosine receptor-mediated Ins(1,4,5)P3 generation in allergic rabbit airway smooth muscle. Am J Physiol275:L990-L997, 1998.
58.
58. Parsons M, Young L, Lee JE, et al: Distinct cardioprotective effects of adenosine mediated by differential coupling of receptor subtypes to phospholipases C and D. FASEB J14:1423-1431, 2000.
59.
59. Liang BT: Direct preconditioning of cardiac ventricular myocytes via adenosine Al receptor and KATP channel. Am J Physiol271:H1769-H1777, 1996.
60.
60. Noguchi J, Yamashita H: Adenosine inhibits voltage-dependent Ca2+ currents in rat dissociated supraoptic neurones via Al receptors. J Physiol526(Pt 2):313-326, 2000.
61.
61. Ambrosio AF, Malva JO, Carvalho AP, et al: Inhibition of N-,P/Qand other types of Ca2+ channels in rat hippocampal nerve terminals by the adenosine Al receptor. Eur J Pharmacol340:301-310, 1997.
62.
62. Marala RB, Mustafa SJ: Direct evidence for the coupling of A2-adenosine receptor to stimulatory guanine nucleotidebinding-protein in bovine brain striatum. J Pharmacol Exp Ther266:294-300, 1993.
63.
63. Stefanovic V, Vlahovic P.Savic V, et al: Adenosine stimulates 5'-nucleotidase activity in rat mesangial cells via A2 receptors. FEBS Lett331:96-100, 1993.
64.
64. MacEwan DJ, Kim GD, Milligan G: Agonist regulation of adenylate cyclase activity in neuroblastoma x glioma hybrid NG108-15 cells transfected to co-express adenylate cyclase type II and the beta 2-adrenoceptor. Evidence that adenylate cyclase is the limiting component for receptormediated stimulation of adenylate cyclase activity. Biochem J318:1033-1039, 1996.
65.
65. Li SN, Wong PT: The adenosine receptor agonist, APNEA, increases calcium influx into rat cortical synaptosomes through N-type channels associated with A2a receptors. Neurochem Res25:457-459, 2000.
66.
66. Palmer TM, Gettys TW, Stiles GL: Differential interaction with and regulation of multiple G-proteins by the rat A3 adenosine receptor. J Biol Chem270:16895-16902, 1995.
67.
67. Atkinson MR, Townsend-Nicholson A, Nicholl JK, et al: Cloning, characterisation and chromosomal assignment of the human adenosine A3 receptor (ADORA3) gene. Neurosci Res29:73-79, 1997.
68.
68. Abbracchio MP, Brambilla R, Ceruti S, et al: G protein-dependent activation of phospholipase C by adenosine A3 receptors in rat brain. Mol Pharmacol48:1038-1045, 1995.
69.
69. Zhao Z, Francis CE, Ravid K: An A3-subtype adenosine receptor is highly expressed in rat vascular smooth muscle cells: Its role in attenuating adenosine-induced increase in cAMP. Microvasc Res54:243-252, 1997.
70.
70. Zhao Z, Makaritsis K, Francis CE, et al: A role for the A3 adenosine receptor in determining tissue levels of cAMP and blood pressure: Studies in knock-out mice. Biochim Biophys Acta1500:280-290, 2000.
71.
71. McCormack DG, Clarke B, Barnes PJ: Characterization of adenosine receptors in human pulmonary arteries. Am J Physiol256:H41-H46, 1989.
72.
72. Reviriego J, Alonso MJ, Ibanez C, et al: Action of adenosine and characterization of adenosine receptors in human placental vasculature. Gen Pharmacol21:227-233, 1990.
73.
73. Sabouni MH, Hussain T, Cushing DJ, et al: G proteins subserve relaxations mediated by adenosine receptors in human coronary artery. J Cardiovasc Pharmacol18:696-702, 1991.
74.
74. Kemp BK, Cocks TM: Adenosine mediates relaxation of human small resistance-like coronary arteries via A2B receptors. Br J Pharmacol126:1796-1800, 1999.
75.
75. Habazettl H, Conzen PF, Vollmar B, et al: Dilation of coronary microvessels by adenosine induced hypotension in dogs. Int J Microcirc Clin Exp11:51-65, 1992.
76.
76. Habazettl H, Vollmar B, Christ M, et al: Heterogeneous microvascular coronary vasodilation by adenosine and nitroglycerin in dogs. J Appl Physiol76:1951-1960, 1994.
77.
77. DeFily DV, Patterson JL, Chilian WM: Endogenous adenosine modulates alpha 2-but not alpha 1-adrenergic constriction of coronary arterioles. Am J Physiol268:H2487-H2494, 1995.
78.
78. Doyle MP, Linden J.Duling BR: Nucleoside-induced arteriolar constriction: A mast cell-dependent response. Am J Physiol266:H2042-H2050, 1994.
79.
79. Shepherd RK, Linden J, Duling BR: Adenosine-induced vasoconstriction in vivo. Role of the mast cell and A3 adenosine receptor. Circ Res78:627-634, 1996.
81. Koch LG, Britton SL, Metting PJ: Adenosine is not essential for exercise hyperaemia in the hindlimb of conscious dogs. J Physiol429:63-76, 1990.
82.
82. Bassenge E, Heusch G: Endothelial and neuro-humoral control of coronary blood flow in health and disease. Rev Physiol Biochem Pharmacol116:77-165, 1990.
83.
83. Michel T, Feron O: Nitric oxide synthases: Which, where, how, and why?J Clin Invest100:2146-2152, 1997.
84.
84. Rapoport RM, Murad F: Endothelium-dependent and nitrovasodilator-induced relaxation of vascular smooth muscle: Role of cyclic GMP. J Cyclic Nucleotide Protein Phosphor Res9:281-296, 1983.
85.
85. Mayer B, Pfeiffer S, Schrammel A, et al: A new pathway of nitric oxide/cyclic GMP signaling involving Snitrosoglu-tathione. J Biol Chem273:3264-3270, 1998.
86.
86. Lincoln TM: Cyclic GMP and mechanisms of vasodilation. Pharmacol Ther41:479-502, 1989.
88. White KA, Marletta MA: Nitric oxide synthase is a cytochrome P-450 type hemoprotein. Biochemistry31:6627-6631, 1992.
89.
89. Forstermann U., Pollock JS, Schmidt HH, et al: Calmodulin-dependent endothelium-derived relaxing factor/nitric oxide synthase activity is present in the particulate and cytosolic fractions of bovine aortic endothelial cells. Proc Natl Acad Sci USA88:1788-1792, 1991.
90.
90. Chen XL, Rembold CM: Cyclic nucleotide-dependent regulation of Mn2+ influx, [Ca2+]i, and arterial smooth muscle relaxation. Am J Physiol263:C468-C473, 1992.
91.
91. Hirata M, Kohse KP, Chang CH, et al: Mechanism of cyclic GMP inhibition of inositol phosphate formation in rat aorta segments and cultured bovine aortic smooth muscle cells. J Biol Chem265:1268-1273, 1990.
92.
92. Holzmann S: Endothelium-induced relaxation by acetylcholine associated with larger rises in cyclic GMP in coronary arterial strips. J Cyclic Nucleotide Res8:409-419, 1982.
93.
93. Light DB, Corbin JD, Stanton BA: Dual ion-channel regulation by cyclic GMP and cyclic GMP-dependent protein kinase. Nature344:336-339, 1990.
94.
94. Rapoport RM: Cyclic guanosine monophosphate inhibition of contraction may be mediated through inhibition of phosphatidylinositol hydrolysis in rat aorta. Circ Res58:407-410, 1986.
95.
95. Rumbaut RE, McKay MK, Huxley VH: Capillary hydraulic conductivity is decreased by nitric oxide synthase inhibition. Am J Physiol268:H1856-H1861, 1995.
96.
96. Kubes P: Nitric oxide affects microvascular permeability in the intact and inflamed vasculature. Microcirculation2:235-244, 1995.
97.
97. Kubes P: Nitric oxide-induced microvascular permeability alterations: A regulatory role for cGMP. Am J Physiol265:H1909-H1915, 1993.
98.
98. Arnhold S, Antoine D, Blaser H, et al: Nitric oxide decreases microvascular permeability in bradykinin stimulated and nonstimulated conditions. J Cardiovasc Pharmacol33:938-947, 1999.
99.
99. Sagach VF, Kindybalyuk AM, Kovalenko TN: Functional hyperemia of skeletal muscle: Role of endothelium. Journal of Cardiovascular Pharmacology20:S170-S175, 1992.
100.
100. Johnston CI, Risvanis J: Preclinical pharmacology of angiotensin II receptor antagonists: Update and outstanding issues. Am J Hypertens10:306S-310S, 1997.
101.
101. Griendling KK, Ushio-Fukai M, Lassegue B, et al: Angiotensin II signaling in vascular smooth muscle. New concepts. Hypertension29:366-373, 1997.
102.
102. Harrison DG: Endothelial function and oxidant stress. Clin Cardiol20:II-11-17-II-11-17, 1997.
103.
103. Warnholtz A, Nickenig G, Schulz E, et al: Increased NADH-oxidase-mediated superoxide production in the early stages of atherosclerosis: Evidence for involvement of the renin-angiotensin system. Circulation99:2027-2033, 1999.
104.
104. Nakashima M, Vanhoutte PM: Age-dependent decrease in endothelium-dependent hyperpolarizations to endothelin-3 in the rat mesenteric artery. J Cardiovasc Pharmacol22:S352-S354, 1993.
105.
105. Nelson MT, Patlak JB, Worley JF, et al: Calcium channels, potassium channels, and voltage dependence of arterial smooth muscle tone. Am J Physiol259:C3-C18, 1990.
106.
106. Beny JL, Gribi F: Dye and electrical coupling of endothelial cells in situ. Tissue Cell21:797-802, 1989.
107.
107. Beny JL, Pacicca C: Bidirectional electrical communication between smooth muscle and endothelial cells in the pig coronary artery. Am J Physiol266:H1465-H1472, 1994.
108.
108. Marchenko SM, Sage SO: Electrical properties of resting and acetylcholine-stimulated endothelium in intact rat aorta. J Physiol462:735-751, 1993.
109.
109. Campbell WB, Harder DR: Endothelium-derived hyperpolarizing factors and vascular cytochrome P450 metabolites of arachidonic acid in the regulation of tone. Circ Res84:484-488, 1999.
110.
110. Randall MD, Kendall DA: Involvement of a cannabinoid in endothelium-derived hyperpolarizing factor-mediated coronary vasorelaxation. Eur J Pharmacol335:205-209, 1997.
111.
111. Niederhoffer N, Szabo B: Involvement of CB1 cannabinoid receptors in the EDHF-dependent vasorelaxation in rabbits. Br J Pharmacol126:1383-1386, 1999.
